Nantahala Capital Management LLC Has $7.98 Million Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Key Points

• Nantahala Capital Management LLC increased its stake in Centessa Pharmaceuticals by 8.2%, owning approximately 0.42% of the company, valued at $7,978,000.
• Major ratings for CNTA include a "buy" from Needham & Company with a price target of $35.00, while Oppenheimer set an "outperform" rating with a target of $40.00.
• Insider sales included General Counsel Iqbal J. Hussain selling 6,000 shares for $103,380, reflecting a decrease in their ownership by 5.39%.

Nantahala Capital Management LLC increased its stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) by 8.2% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 554,803 shares of the company's stock after purchasing an additional 42,156 shares during the quarter. Nantahala Capital Management LLC owned approximately 0.42% of Centessa Pharmaceuticals worth $7,978,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Armistice Capital LLC bought a new position in Centessa Pharmaceuticals in the 1st quarter worth approximately $6,730,000. Trexquant Investment LP increased its position in Centessa Pharmaceuticals by 1.1% in the 1st quarter. Trexquant Investment LP now owns 263,994 shares of the company's stock worth $3,796,000 after buying an additional 2,810 shares during the period. Affinity Asset Advisors LLC increased its position in Centessa Pharmaceuticals by 41.1% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,546,662 shares of the company's stock worth $22,241,000 after buying an additional 450,738 shares during the period. Walleye Capital LLC bought a new position in Centessa Pharmaceuticals in the 1st quarter worth approximately $1,182,000. Finally, Osterweis Capital Management Inc. bought a new position in Centessa Pharmaceuticals in the 1st quarter worth approximately $47,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Price Performance

NASDAQ:CNTA traded down $0.12 during trading hours on Thursday, reaching $15.79. The company had a trading volume of 905,511 shares, compared to its average volume of 973,116. The stock has a 50-day moving average of $15.88 and a two-hundred day moving average of $14.47. Centessa Pharmaceuticals PLC Sponsored ADR has a one year low of $9.60 and a one year high of $19.09. The firm has a market capitalization of $2.11 billion, a PE ratio of -8.82 and a beta of 1.47. The company has a quick ratio of 10.12, a current ratio of 10.11 and a debt-to-equity ratio of 0.32.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.03). Analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on CNTA. Chardan Capital reaffirmed a "buy" rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a research report on Tuesday, August 12th. Needham & Company LLC began coverage on Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 price target on the stock. Lifesci Capital raised Centessa Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday. Wall Street Zen cut Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Finally, Truist Financial started coverage on Centessa Pharmaceuticals in a research report on Monday, July 21st. They set a "buy" rating and a $30.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating and twelve have assigned a Buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $31.45.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider Mario Alberto Accardi sold 15,000 shares of the business's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $14.00, for a total value of $210,000.00. Following the transaction, the insider owned 216,485 shares of the company's stock, valued at approximately $3,030,790. The trade was a 6.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Iqbal J. Hussain sold 12,000 shares of the business's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $14.02, for a total value of $168,240.00. Following the completion of the transaction, the general counsel directly owned 105,386 shares in the company, valued at approximately $1,477,511.72. This represents a 10.22% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 171,322 shares of company stock worth $2,472,814 in the last three months. Company insiders own 7.09% of the company's stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.